Study of DZD8586 vs. standard care for relapsed CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with CLL or SLL that has come back or is not responding to treatment, and you need more therapy.
- You are in good enough health to walk and care for yourself (able to do daily activities).
- Your bone marrow and major organs are working well enough.
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
This study tests a new targeted drug (DZD8586) in combination with other therapies for people who have just been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and have not yet received any treatment. The goal is to see if this combination works better than current standard treatments.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hear when a new Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.